+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID07391774

Comparing Hormone Therapy Plus Ribociclib Versus Chemotherapy Followed by Hormone Therapy Plus Ribociclib for High Anatomic Stage Breast Cancer with Low Recurrence Risk

Led by National Cancer Institute (NCI) · Updated on 2026-11-04

1978

Participants Needed

248

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating two treatment approaches for patients with high anatomic stage breast cancer that has a low risk of returning. This phase III trial compares standard hormone therapy combined with ribociclib to chemotherapy followed by hormone therapy and ribociclib. Ribociclib works by blocking enzymes needed for tumor growth, and hormone therapy reduces estrogen levels to help stop the growth of cancer cells that depend on estrogen. Chemotherapy works differently by killing or stopping the division and spread of tumor cells. Participants are first screened using the Oncotype DX test to assess their recurrence risk. Those with scores between 0 and 25 are randomized into one of two groups. One group receives their physicians choice of chemotherapy followed by hormone therapy letrozole, anastrozole, or exemestane plus ribociclib. The other group receives hormone therapy plus ribociclib without chemotherapy. Hormone therapy is taken daily for at least 60 months, and ribociclib is taken daily for up to 3 years unless disease progression or unacceptable side effects occur. Throughout the study, participants may undergo imaging scans such as CT, bone scans, or FDG PET-CT scans, and may optionally provide blood samples. Participants are monitored with follow-up visits every 3 months for the first year, every 6 months during years 1 to 5, and annually from years 5 to 10 after randomization. Researchers will assess invasive breast cancer-free survival as the main outcome, along with disease-free survival, overall survival, recurrence measures, and both short- and long-term side effects. The study also plans to collect tumor tissue and blood samples to support future research. Total participation may last up to 10 years to evaluate long-term outcomes and safety.

CONDITIONS

Brief Title

Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here